Skip to main content Accessibility help
×
Hostname: page-component-8448b6f56d-qsmjn Total loading time: 0 Render date: 2024-04-20T02:58:46.349Z Has data issue: false hasContentIssue false

11 - Compounds acting on ion channels

from Part I - Basic aspects of neurodegeneration

Published online by Cambridge University Press:  04 August 2010

M. Flint Beal
Affiliation:
Cornell University, New York
Anthony E. Lang
Affiliation:
University of Toronto
Albert C. Ludolph
Affiliation:
Universität Ulm, Germany
Holger Lerche
Affiliation:
Departments of Neurology and Applied Physiology, University of Ulm, Germany
Frank Lehmann-Horn
Affiliation:
Departments of Neurology and Applied Physiology, University of Ulm, Germany
Get access

Summary

Important factors of neuronal death in various diseases ranging from acute illness such as head trauma or stroke to rapidly or slowly progressive disorders such as amyotrophic lateral sclerosis or idiopathic parkinsonism are energy deficit and membrane depolarization. The communication of nerve cells via action potentials and synaptic transmission needs a highly negative resting membrane potential as well as strong transmembrane ionic gradients, which guarantee a regulated ion flow across the membrane. A large part of the energy demand of neurons is therefore required for active ionic pumps such as the Na/K ATPase. A reduction of membrane excitability preventing membrane depolarization and decreasing the transmembrane ionic flow therefore diminishes the energy demand of neurons considerably. The pharmacological modification of the gating of voltage- or ligand-activated ion channels thus provides potentially powerful strategies for neuroprotection. The block of voltage-gated sodium or calcium channels directly reduces the influx of respective ions and decreases excitability, whereas the activation of potassium channels leads to a membrane hyperpolarization reducing excitability and secondarily influx of sodium and calcium through voltage-gated channels and other mechanisms. These neuroprotective strategies, the targets and compounds used for pharmacotherapy and available studies in animal models and humans are discussed in this chapter. The concept of excitoxicity and neuroprotection by its antagonism by a block of glutamate receptors belonging to the group of ligand-gated ion channels is discussed in Chapter 4 of this book.

Type
Chapter
Information
Neurodegenerative Diseases
Neurobiology, Pathogenesis and Therapeutics
, pp. 141 - 145
Publisher: Cambridge University Press
Print publication year: 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bensimon, G., Lacomblez, L. & Meininger, V. (1994). A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N. Engl. J. Med., 330, 585–91CrossRefGoogle ScholarPubMed
Bowersox, S. S. & Luther, R. (1998). Pharmacotherapeutic potential of ω-conotoxin MVIIA (SNX-111), an N-type neuronal calcium channel blocker found in the venom of Conus magus. Toxicon, 36, 1651–8CrossRefGoogle Scholar
Catterall, W. A. (2000a). From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. Neuron, 26, 13–25CrossRefGoogle Scholar
Catterall, W. A. (2000b). Structure and regulation of voltage-gated calcium channels. Annu. Rev. Cell. Dev. Biol., 16, 521–55CrossRefGoogle Scholar
Doble, A. (1997). Effects of riluzole on glutamatergic neurotransmission in the mammalian central nervous system, and other pharmacological effects. Rev. Contemp. Pharmacother., 8, 213–25Google Scholar
Doyle, D. A., Morais Cabral, J., Pfuetzner, R. A.et al. (1998). The structure of the K+ channel: molecular basis of K+ conduction and selectivity. Science, 280, 69–77CrossRefGoogle Scholar
Duprat, F., Lesage, F., Patel, A. J., Fink, M., Romey, G. & Lazdunski, M. (2000). The neuroprotective agent riluzole activates the two P domain K+ channels TREK-1 and TRAAK. Mol. Pharmacol., 57, 906–12Google ScholarPubMed
Galli, C., Meucci, O., Scorziello, A., Werge, T. M., Calissano, P. & Schettini, G. (1995). Apoptosis in cerebellar granule cells is blocked by high KCl, forskolin, and IGF-1 through distinct mechanisms of action: the involvement of intracellular calcium and RNA synthesis. J. Neurosci., 15, 1172–9CrossRefGoogle ScholarPubMed
Gribkoff, V. K., Starrett, J. E. Jr., Dworetzky, S. I.et al. (2001). Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels. Nat. Med., 7, 471–7CrossRefGoogle ScholarPubMed
Hansen, A. J. (1985). Effects of anoxia on ion distribution in the brain. Physiol. Rev. 65, 101–48CrossRefGoogle Scholar
Heurteaux, C., Bertaina, V., Widmann, C. & Lazdunski, M. (1993). K+ channel openers prevent global ischemia-induced expression of c-fos, c-jun, heat shock protein, and amyloid beta-protein precursor genes and neuronal death in rat hippocampus. Proc. Natl Acad. Sci., USA, 90, 9431–5CrossRefGoogle ScholarPubMed
Hille, B. (2001). Ion Channels of Excitable Membranes. Sunderland, Massachusetts, USA: Sinauer Associates Inc
Horn, J. & Limburg, M. (2001). Calcium antagonists for ischemic stroke: a systematic review. Stroke, 32, 570–6CrossRefGoogle ScholarPubMed
Horn, J., Haan, R. J., Vermeulen, M., Luiten, P. G. & Limburg, M. (2001). Nimodipine in animal model experiments of focal cerebral ischemia: a systematic review. Stroke, 32, 2433–8CrossRefGoogle ScholarPubMed
Jensen, B. S. (2002). BMS-204352: a potassium channel opener developed for the treatment of stroke. CNS Drug Rev., 8, 353–60CrossRefGoogle ScholarPubMed
Kobayashi, T. & Mori, Y. (1998). Ca2+ channel antagonists and neuroprotection from cerebral ischemia. Eur. J. Pharmacol., 363, 1–15CrossRefGoogle ScholarPubMed
Koh, J.-Y. & Cotman, C. W. (1992). Programmed cell death: its possible contribution to neurotoxicity mediated by calcium channel antagonists. Brain Res., 587, 233–40CrossRefGoogle ScholarPubMed
Liss, B., Bruns, R., & Roeper, J., (1999). Alternative sulfonylurea receptor expression defines metabolic sensitivity of K-ATP channels in dopaminergic midbrain neurons. EMBO J., 18, 833–46CrossRefGoogle ScholarPubMed
Milhaud, D., Fagni, L., Bockaert, J., & Lafon-Cazal, M., (2002). Inhibition of voltage-gated Ca2+ channels by antazoline.NeuroReport, 13, 1711–14CrossRef
Obrenovitch, T. P. & Urenjak, J. (1997). Actions of riluzole in animal models of CNS ischemia and trauma. Rev. Contemp. Pharmacother., 8, 227–35Google Scholar
Patel, A. J. & Honore, E., (2001). Properties and modulation of mammalian 2P domain K+ channels. Trends Neurosci., 24, 339–46CrossRefGoogle ScholarPubMed
Perez-Pinzon, M. A., Yenari, M. A., Sun, G. H., Kunis, D. M. & Steinberg, G. K. (1997). SNX-111, a novel, presynaptic N-type calcium channel antagonist, is neuroprotective against focal cerebral ischemia in rabbits. J. Neurol. Sci., 153, 25–31CrossRefGoogle ScholarPubMed
Riepe, M., Hori, N., Ludolph, A. C., Carpenter, D. O., Spencer, P. S. & Allen, C. N. (1992). Inhibition of energy metabolism by 3-nitropropionic acid activates ATP-sensitive potassium channels. Brain Res., 586, 61–6CrossRefGoogle ScholarPubMed
Riepe, M. W., Esclaire, F., Kasischke, K.et al. (1997). Increased hypoxic tolerance by chemical inhibition of oxidative phosphorylation: ‘chemical preconditioning’. J. Cereb. Blood Flow Metab., 17, 257–64CrossRefGoogle Scholar
Taylor, C. P. & Meldrum, B. S. (1995). Na+ channels as targets for neuroprotective drugs. Trends Pharmacol. Sci., 16, 309–16CrossRefGoogle ScholarPubMed
Urenjak, J. & Obrenovitch, T. P. (1996). Pharmacological modulation of voltage-gated Na+ channels: a rational and effective strategy against ischemic brain damage. Pharmacol. Rev., 48, 21–67Google ScholarPubMed
Yoo, S. E., Yi, K. Y., Lee, S.et al. (2001). A novel anti-ischemic ATP-sensitive potassium channel (K(ATP)) opener without vasorelaxation: N-(6-aminobenzopyranyl)-N′-benzyl-N″-cyanoguanidine analogue. J. Med. Chem., 44, 4207–15CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×